Lifeline offered for rare growth disorder patients
NCT ID NCT04085653
Summary
This program provides access to the drug alpelisib for patients with PIK3CA-Related Overgrowth Spectrum (PROS), a rare genetic condition causing abnormal tissue growth. It's designed for patients with severe or life-threatening cases who have no other feasible treatment options. The program allows doctors to use this medication while following specific safety guidelines and monitoring requirements.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.